BioSpace News Archive

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its second quarter 2019 financial results and provide a corporate update on Tuesday, August 6, 2019.

Certara®, the global model-informed drug development and decision support leader, today announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development

The not-for-profit community medical center is partnering with Glytec to facilitate standardization of best practices in diabetes therapy management.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019.

Each company will receive business and technology mentorship from DuPont and 1 year of free access to laboratories and startup support services of the Delaware Innovation Space

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of patients with moderate-to-severe binge eating disorder (BED).

DSFederal announced that it has expanded its long history of work supporting the National Institutes of Health through a new contract to provide a wide range of scientific and program support services, including highly qualified technical and scientific analytics experts, to the Office of Extramural Research.

Solidifying their commitment to veterinary practice excellence and their status as the industry’s definitive data experts, VetSuccess is now proud to partner with the American Animal Hospital Association (AAHA).

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.

Camber Spine, a leading innovator in spine and medical technologies, today announced the implantation of their first oblique lumbar interbody fusion (OLIF) specific device from the SPIRA® family using the company’s proprietary SPIRA®-O Open Matrix OLIF, a unique, interbody fusion implant consisting of spiral support arches and Surface by Design™ technology.